BTAI — BioXcel Therapeutics, Inc.

Summary of BioXcel Therapeutics Q3 2024 Earnings Call

1. Key Financial Results and Metrics

• Net Revenue: $214,000 for Q3 2024, down from $341,000 in Q3 2023. This decline was attributed to the timing of reorders.
• Year-to-Date Revenue: $1.9 million for the nine months ending September 30, 2024, an 89% increase from $1 million during the same period in 2023, driven by new customer acquisitions and increased sales activity.
• Cost of Goods Sold: Increased to $1.2 million in Q3 2024 from $512,000 in Q3 2023, primarily due to higher reserves for excess or obsolete inventory.
• Research and Development Expenses: $5.1 million in Q3 2024, significantly reduced from $19.6 million in Q3 2023, reflecting a reprioritization and reduction in workforce.
• Selling, General, and Administrative Expenses: $7.7 million in Q3 2024, down from $24.3 million in Q3 2023, due to decreased personnel costs and professional fees.
• Net Loss: $13.7 million for Q3 2024, a notable improvement compared to a net loss of $50.5 million in Q3 2023.
• Cash Position: $40.4 million in cash and cash equivalents as of September 30, 2024.

2. Strategic Updates and Business Highlights

• BXCL501 Trials: The company is advancing two pivotal Phase 3 trials for BXCL501 targeting agitation associated with bipolar disorder and Alzheimer's dementia. The SERENITY trial has commenced with the first patient randomized, while planning for the TRANQUILITY trial is ongoing.
• External Funding: A Department of Defense grant has been secured to fund a Phase 2a study for acute stress disorder, reflecting BXCL501's broad therapeutic potential.
• IGALMI: The company continues to market IGALMI with minimal resources, focusing on maintaining brand equity while supporting ongoing clinical trials.

3. Forward Guidance and Outlook

• Trial Duration: The SERENITY trial is expected to take 9 to 12 months, with data readouts anticipated in 2025.
• Financial Strategy: The company is actively exploring strategic financing options to strengthen its balance sheet while progressing towards key data readouts.

4. Bad News, Challenges, or Points of Concern

• Declining Revenue: Despite year-to-date growth, the quarterly revenue decline raises concerns about sales momentum and customer reorder patterns.
• Increased Costs: Rising costs of goods sold and the need for inventory write-downs could impact profitability.
• Cash Runway: While the company has a cash position of $40.4 million, there are questions regarding whether this will be sufficient to fund ongoing trials and operations until the next data readouts.

5. Notable Q&A Insights

• SERENITY Study Enrollment: The ramp-up phase for patient enrollment is underway, with expectations for a rebound in January following the holiday season.
• FDA Feedback: The company received actionable feedback from the FDA regarding the TRANQUILITY trial protocol, which was described as concise and positive.
• Partnership Opportunities: Successful completion of the SERENITY trial is seen as crucial for unlocking potential partnerships in the at-home agitation market.
• BXCL701 Progress: Ongoing discussions with potential partners for BXCL701 are taking longer than anticipated, indicating a cautious approach to its development.

Overall, BioXcel Therapeutics is making progress in its clinical trials and has shown improvements in financial metrics, but faces challenges related to revenue generation and cash management as it seeks to navigate its strategic initiatives.